All In Biotech

BLA 125399 · Seattle Genetics

Adcetris

Brentuximab Vedotin · Injection

Last checked: Nov 20, 2026Latest source record: Aug 19, 2011 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Aug 19, 2011

Approved uses

1

Original approval plus efficacy supplements

Registered trials

189

19 Phase 3, 23 recruiting

FAERS reports

10,402

9,478 serious, 1,994 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ADCETRIS · BRENTUXIMAB VEDOTIN 50MG/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Brentuximab Vedotin" as an intervention, any sponsor and status, largest first.

All 189 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,358
  • febrile neutropenia776
  • neuropathy peripheral725
  • pyrexia694
  • neutropenia599
  • death594
  • hodgkin^s disease462
  • nausea407
  • anaemia399
  • thrombocytopenia388
  • diarrhoea387
  • drug ineffective378

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201116
2012151
2013182
2014294
2015377
2016453
2017609
2018677
2019887
2020940
2021927
2022821
2023855
20241,517
20251,040
2026656

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Adcetris (Brentuximab Vedotin)

2024 spending

$3.5M

Beneficiaries

25

106 claims

Per beneficiary

$140,843

$11,107.46 per unit

View as table
YearSpending
2020$1,207,676
2021$2,395,839
2022$3,044,765
2023$3,056,726
2024$3,521,063

Part B: Adcetris (Brentuximab Vedotin) · HCPCS J9042

2024 spending

$187M

Beneficiaries

1,363

6,255 claims

Per beneficiary

$137,180

2024 ASP limit $235.20 per unit

View as table
YearSpending
2020$161,368,351
2021$164,383,360
2022$186,209,799
2023$193,419,173
2024$186,976,535

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 226 on PubMed

Sponsor: Seattle Genetics

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.